Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 81 to 90 of 220 total matches.
Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC
The Medical Letter on Drugs and Therapeutics • Jun 08, 2015 (Issue 1470)
on or after platinumbased
chemotherapy. It is the second PD-1 inhibitor to
be marketed in the US after ...
The FDA has approved nivolumab (Opdivo – BMS),
an IV programmed death receptor-1 (PD-1) blocking
antibody, for treatment of unresectable or metastatic
melanoma that has progressed following treatment
with ipilimumab (and a BRAF inhibitor in patients who
are BRAF V600 mutation positive) and for treatment
of metastatic squamous non-small cell lung cancer
(NSCLC) that has progressed on or after platinum-based
chemotherapy. It is the second PD-1 inhibitor to
be marketed in the US after pembrolizumab (Keytruda),
and the first to be approved for treatment of NSCLC.
Invader UGT1A1 Molecular Assay for Irinotecan Toxicity
The Medical Letter on Drugs and Therapeutics • May 08, 2006 (Issue 1234)
........................................p 39
A genetic test for an increased risk of toxicity from the
cancer chemotherapy drug irinotecan ...
The FDA has approved a new genetic test to identify patients who may be at increased risk of severe toxicity when treated with the cancer chemotherapy drug irinotecan (Camptosar). The Invader UGT1A1 Molecular Assay (Third Wave Technologies) detects the UGT1A1*28 allele, a variation in the uridine diphosphate glucuronosyltranferase 1A1 (UGT1A1) gene. The FDA recently revised the safety labeling for irinotecan, recommending that the dosing of irinotecan be reduced for patients who are homozygous for the UGT1A1*28 allele.
Medical Marijuana
The Medical Letter on Drugs and Therapeutics • Jan 25, 2010 (Issue 1330)
) have both been FDA-approved
since 1985 for treatment of chemotherapy-induced
nausea and vomiting ...
Fourteen states in the US - Alaska, California, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont and Washington - now permit, or soon will permit, some medical use of marijuana (Cannabis sativa). In some states, licensed facilities dispense botanical cannabis by prescription. In others, limited self-cultivation is permitted for medical use.
Dolutegravir (Tivicay) for HIV
The Medical Letter on Drugs and Therapeutics • Sep 30, 2013 (Issue 1426)
on
Antimicrobial Agents and Chemotherapy. San Francisco, CA; September 9-
12, 2012. Available at www.natap.org ...
The FDA has approved dolutegravir (doll-you-TEG-rah-veer;
Tivicay – Viiv Healthcare), an integrase strand
transfer inhibitor (INSTI), for treatment of HIV-1 infection
in adults and in children ≥12 years old who weigh at least 40 kg. It is the third INSTI to be approved by the FDA; raltegravir
and elvitegravir were approved earlier.
Albumin-Bound Paclitaxel (Abraxane) for Advanced Breast Cancer
The Medical Letter on Drugs and Therapeutics • May 09, 2005 (Issue 1208)
after failure of combination chemotherapy or relapse within 6 months of adjuvant
chemotherapy.
1 ...
A new albumin-bound formulation of paclitaxel (Abraxane - American Pharmaceutical Partners) has been approved by the FDA for treatment of metastatic breast cancer after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy. This formulation is free of polyoxyethylated castor oil (Cremophor), a solvent thought to contribute to the hypersensitivity reactions that occur frequently with standard paclitaxel (Taxol, and others) and are severe in about 3% of patients.
Eribulin Mesylate (Halaven) for Breast Cancer
The Medical Letter on Drugs and Therapeutics • Apr 18, 2011 (Issue 1362)
at least 2 chemotherapy regimens for
metastatic cancer. Prior therapy should have
included ...
Eribulin mesylate (Halaven – Eisai) has been
approved by the FDA for treatment of patients with
metastatic breast cancer who have previously
received at least 2 chemotherapy regimens for
metastatic cancer. Prior therapy should have
included an anthracycline and a taxane in either an
adjuvant or metastatic setting. Other drugs used to
treat anthracycline- and taxane-refractory metastatic
breast cancer include capecitabine (Xeloda),
gemcitabine (Gemzar, and others) and vinorelbine
(Navelbine, and others).
Umbilical Cord Blood for Bone Marrow Transplantation
The Medical Letter on Drugs and Therapeutics • Aug 16, 1996 (Issue 981)
FOR
ONLINE USERS
UMBILICAL CORD BLOOD FOR BONE MARROW TRANSPLANTATION
High-dose chemotherapy followed ...
High-dose chemotherapy followed by bone marrow transplantation continues to be widely used in the treatment of malignant diseases (Medical Letter, 37:25, 1995). The source of the transplant has been autologous or allogeneic bone marrow or, more recently, stem and progenitor cells harvested from peripheral blood (Medical Letter, 37:71, 1995). Now, blood taken from the umbilical cord and placenta of a newborn infant is being tried as a source of cells to restore the bone marrow. A single collection of umbilical cord blood contains about as many progenitor cells as most autologous bone...
Palifermin (Kepivance) for Myelotoxic-Therapy-Related Mucositis
The Medical Letter on Drugs and Therapeutics • Apr 25, 2005 (Issue 1207)
myelotoxic chemotherapy and hematopoietic stem cell
support. It appears to be well tolerated and could ...
Palifermin (Kepivance - Amgen), a recombinant human keratinocyte growth factor (KGF), has been approved by the FDA to decrease the incidence and duration of severe oral mucositis (OM) in patients with hematologic malignancies receiving myelotoxic chemotherapy and hematopoietic stem cell (HSC) rescue.
Mirvetuximab Soravtansine (Elahere) for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
mirvetuximab
soravtansine or chemotherapy (paclitaxel, pegylated
liposomal doxorubicin, or topetecan ...
Mirvetuximab soravtansine-gynx (Elahere – Immuno-Gen), an antibody-drug conjugate, has received
accelerated approval by the FDA for treatment
of folate receptor (FR) alpha-positive, platinum-resistant
epithelial ovarian, fallopian tube, or primary
peritoneal cancer in adults who received 1-3 prior
lines of systemic therapy. Accelerated approval
was based on the overall response rate and median
duration of response.
Lifileucel (Amtagvi): A Cellular Therapy for Melanoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024 (Issue 1701)
infusion of lifileucel (7.5 x 109 - 72 x 109
viable cells) after lymphodepleting chemotherapy.
▶ Cost ...
Lifileucel (Amtagvi – Iovance), a tumor-derived
autologous T-cell immunotherapy, has received
accelerated approval from the FDA for one-time
treatment of adults with unresectable or metastatic
melanoma previously treated with a programmed
death receptor-1 (PD-1) inhibitor, and if BRAF V600
mutation-positive, a BRAF inhibitor with or without
a mitogen-activated kinase (MEK) inhibitor. It is the
first cellular therapy to be approved for use in solid
tumors. Accelerated approval of lifileucel was based
on objective response rates.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):e77-8 doi:10.58347/tml.2024.1701h | Show Introduction Hide Introduction